Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment

Charles J. Gibbs, Munro Peacock

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We report a case of sarcoid hypercalcaemia treated with the bisphosphonate, APD 1(3-amino-l-hydroxypropylidene)-1,1-bisphosphonatel. Investigations showed that the hypercalcaemia was associated with a high plasma 1,25 dihydroxy vitamin D concentration. A low dietary intake of calcium partially corrected the hypercalcaemia but APD rapidly nonnalized plasma calcium without reducing the elevated 1,25 dihydroxy vitamin D concentration. The case demonstrates that hypercalcaemia in sarcoidosis results from the effects of 1,25 dihydroxy vitamin D on bone as well as on calcium absorption and that prolonged suppression of the effect on bone occurs with APD treatment.

Original languageEnglish (US)
Pages (from-to)937-938
Number of pages2
JournalPostgraduate Medical Journal
Volume62
Issue number732
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

pamidronate
Diphosphonates
Hypercalcemia
Sarcoidosis
Vitamin D
Calcium
Bone and Bones
Dietary Calcium

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Epidemiology
  • Medicine(all)

Cite this

Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment. / Gibbs, Charles J.; Peacock, Munro.

In: Postgraduate Medical Journal, Vol. 62, No. 732, 1986, p. 937-938.

Research output: Contribution to journalArticle

@article{b13c84f9337e4d3ba6cca8eb0a4607e1,
title = "Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment",
abstract = "We report a case of sarcoid hypercalcaemia treated with the bisphosphonate, APD 1(3-amino-l-hydroxypropylidene)-1,1-bisphosphonatel. Investigations showed that the hypercalcaemia was associated with a high plasma 1,25 dihydroxy vitamin D concentration. A low dietary intake of calcium partially corrected the hypercalcaemia but APD rapidly nonnalized plasma calcium without reducing the elevated 1,25 dihydroxy vitamin D concentration. The case demonstrates that hypercalcaemia in sarcoidosis results from the effects of 1,25 dihydroxy vitamin D on bone as well as on calcium absorption and that prolonged suppression of the effect on bone occurs with APD treatment.",
author = "Gibbs, {Charles J.} and Munro Peacock",
year = "1986",
doi = "10.1136/pgmj.62.732.937",
language = "English (US)",
volume = "62",
pages = "937--938",
journal = "Postgraduate Medical Journal",
issn = "0032-5473",
publisher = "BMJ Publishing Group",
number = "732",

}

TY - JOUR

T1 - Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment

AU - Gibbs, Charles J.

AU - Peacock, Munro

PY - 1986

Y1 - 1986

N2 - We report a case of sarcoid hypercalcaemia treated with the bisphosphonate, APD 1(3-amino-l-hydroxypropylidene)-1,1-bisphosphonatel. Investigations showed that the hypercalcaemia was associated with a high plasma 1,25 dihydroxy vitamin D concentration. A low dietary intake of calcium partially corrected the hypercalcaemia but APD rapidly nonnalized plasma calcium without reducing the elevated 1,25 dihydroxy vitamin D concentration. The case demonstrates that hypercalcaemia in sarcoidosis results from the effects of 1,25 dihydroxy vitamin D on bone as well as on calcium absorption and that prolonged suppression of the effect on bone occurs with APD treatment.

AB - We report a case of sarcoid hypercalcaemia treated with the bisphosphonate, APD 1(3-amino-l-hydroxypropylidene)-1,1-bisphosphonatel. Investigations showed that the hypercalcaemia was associated with a high plasma 1,25 dihydroxy vitamin D concentration. A low dietary intake of calcium partially corrected the hypercalcaemia but APD rapidly nonnalized plasma calcium without reducing the elevated 1,25 dihydroxy vitamin D concentration. The case demonstrates that hypercalcaemia in sarcoidosis results from the effects of 1,25 dihydroxy vitamin D on bone as well as on calcium absorption and that prolonged suppression of the effect on bone occurs with APD treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023001480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023001480&partnerID=8YFLogxK

U2 - 10.1136/pgmj.62.732.937

DO - 10.1136/pgmj.62.732.937

M3 - Article

VL - 62

SP - 937

EP - 938

JO - Postgraduate Medical Journal

JF - Postgraduate Medical Journal

SN - 0032-5473

IS - 732

ER -